SYHA 121-28
Alternative Names: SYHA121-28Latest Information Update: 25 Apr 2023
Price :
$50 *
At a glance
- Originator CSPC Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Gastric cancer
- Preclinical Lung cancer; Oesophageal cancer; Thyroid cancer
Most Recent Events
- 25 Apr 2023 Phase I development is ongoing in China (CSPC Pharmaceutical pipeline, April 2023)
- 25 Apr 2023 Preclinical trials in Lung cancer in China (unspecified route) (CSPC Pharmaceutical pipeline, April 2023)
- 25 Apr 2023 Preclinical trials in Oesophageal cancer in China (unspecified route) (CSPC Pharmaceutical pipeline, April 2023)